David Quinn, MBBS, PhD, FRACP, from the USC Norris Comprehensive Cancer Center, Los Angeles, CA, presents the latest updates from the ATLAS study (NCT01599754), a clinical trial in which high-risk renal cell carcinoma patients received the VEGF tyrosine kinase inhibitor, axitinib or placebo. Interim analysis saw no significant difference in the two arms, however, later analysis found a significant benefit in the highest risk patients receiving axitinib. Following these positive results, further investigations will look into optimal dosing of axitinib in high-risk patients. This interview was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.